Bill would expand 340B discounts for orphan drugs
Reps. Peter Welch (D-VT) and Gregg Harper (R-MS) yesterday introduced the Closing Loopholes for Orphan Drugs Act (H.R. 2889, legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals. Specifically, the legislation would allow 340B critical access hospitals, sole community providers, rural referral centers and free-standing cancer hospitals to purchase orphan drugs at discounted rates through the 340B program as long as the orphan drug is used to treat illnesses or conditions other than the rare illnesses or conditions for which the orphan drug designation was originally given.
Related News Articles
Headline
The Department of Health and Human Services April 18 finalized its rule to establish a 340B Administrative Dispute Resolution process as required under the…
Headline
Rep. Brett Guthrie, R-Ky., today addressed attendees of AHA’s 2024 Annual Membership Meeting and touched on many of the biggest issues in health care:…
Headline
Sen. John Thune, R-S.D., April 16 updated AHA members on progress to extend telehealth waivers, offering hope that a solution will arise in end-of-year…
Headline
The Change Healthcare cyberattack was a significant event that caught many off guard, said the Centers for Medicare & Medicaid Services Administrator…
Headline
The voluntary Episode Quality Improvement Program for specialist physicians saved Medicare $20 million in its first year, the Maryland Health Services Cost…
Headline
Commenting April 12 on a proposed rule to strengthen oversight of accrediting organizations, AHA told the Centers for Medicare & Medicaid Services it…